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Introduction
The neu oncogene was originally described in NIH3T3 transfectants from ethylnitrosourea-induced tumors in rats ( 1, 2) . The human counterpart, c-erbB-2 or HER-2/neu, encodes a 1 85-kD protein that is homologous to the EGF receptor (EGF-R)' (3, 4) . A point mutation changing a single amino acid in the membrane spanning domain leads to deregulation of tyrosine kinase activity and transformation of cells bearing this mutant protein (5) (6) (7) . A stimulatory ligand for the HER-2/ neu gene product has recently been described (8) . HER-2/neu is amplified and/or overexpressed in -25% of human breast cancer and correlates with advanced disease and poor outcome (9, 10) ; however, the point mutation described for in vitro activation of the HER-2/neu oncogene is absent in the amplified HER-2 / neu oncogene in human tumor specimens ( 11 ) .
The HER-2/neu promoter contains typical CCAAT and TATA elements that are separated by a 45-base segment that is 78% purine on the coding strand ( Fig. 1) ( 12) . A portion ofthis region is homologous to a segment ofthe EGF-R promoter that binds a transcription factor named TC factor (TCF) for the pyrimidine-rich nature of its recognition sequence ( 13 ) . This sequence in the EGF-R promoter appears to be necessary for efficient transcription of EGF-R ( 13), but its function in the HER-2/neu promoter is not known.
Oligonucleotides have now been shown to form interstrand DNA triple helices in a number of naturally occurring purine rich sequences. The promoters of the human c-myc, EGF-R, dihydrofolate reductase (DHFR), and IL-2 receptor (IL-2-R) genes have been successfully targeted for site-specific triplex formation (14) (15) (16) (17) (18) . In addition, sequences in the HIV long terminal repeat (LTR) ( 19) and coding sequence (20) are targets for triplex formation. Triplex formation in DNA target sequences can effectively inhibit protein binding and gene expression (21 ) . The transcription factor Sp I has binding sites in the DHFR promoter; triplex formation at these sites prevents Spl binding ( 17) . In addition, triplex formation prevents nuclear factor kappa B (NFkB) binding to the a-regulatory sequence ofthe IL-2-R promoter ( 18 ) . Triplex-forming oligonucleotides (TFOs) have been shown to inhibit in vitro transcription of c-myc and HIV-LTR ( 15, 19) . Messenger RNA levels of c-myc have been measured in HeLa cells in culture with and without TFO, and these oligonucleotides apparently inhibit cellular c-myc transcription (22) . Cellular IL-2-R transcription is inhibited by a TFO in a chloramphenicol acetyl transferase assay ( 18) , and a TFO has been shown to inhibit HIV transcription and viral proliferation in virally infected cells in culture (19) .
Interstrand DNA triplex formation typically occurs at polypurine/polypyrimidine tracts (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) ). An exogenous polypurine oligonucleotide forms the third strand by occupying the major groove of the native duplex and forming Hoogsteen hydrogen bonds with the purine bases ofthe duplex (23) (24) (25) base triplets in this purine:purine:pyrimidine (R:R:Y) triplex include G:G:C and A:A:T (third strand bases in bold), and the Hoogsteen bonding makes the triplex sequence specific (24, 25) . While purine-rich sequences occur disproportionately in the promoters ofeukaryotic genes (23) , there are often pyrimidines interspersed in the polypurine tract that make triplex formation less favorable. Nonetheless, triplex formation has been shown in several naturally occurring sequences that are not strictly homopurine:homopyrimidine (14) (15) (16) (17) (18) (19) (20) . Pyrimidine interruptions of the polypurine tract potentially disrupt the ability ofthese sequences to form triplex because ofthe loss ofHoogsteen hydrogen bonds (25, 26) . It would be desirable to bridge these interruptions in a manner that minimizes steric interactions that could be destabilizing to triplex formation. An abasic molecule that maintains the proper internucleotide spacing (27) would be ideally suited as such a bridge. We have examined the effect ofsubstituting an abasic bridge for a pyrimidine residue in a purine-rich triplex forming oligonucleotide.
We determined the ability of a polypurine oligonucleotide to form an interstrand triplex with the purine-rich segment of the HER-2/neu promoter from -42 to -69 relative to the major transcription start site. This site was shown to bind nuclear protein from a crude nuclear extract, and the effect of triplex formation on nuclear protein binding to the HER-2/ neu promoter and to the target sequence were also examined. The effect of triplex formation on a cell-free in vitro transcription assay was examined. This target sequence contains a single internal pyrimidine (thymidine at -54) and 
Methods
Oligonucleotide synthesis. Oligonucleotides were synthesized by standard phosphoramidite chemistry on a DNA synthesizer (Cyclone Plus; Millipore Corp., Bedford, MA), purified by reverse phase chromatography (Sep-Pak), and yields were checked by optical density at 260 nm. The integrity ofthe oligonucleotides was verified by gel electrophoresis. Oligonucleotides were labeled by T4 ( 14) . In vitro transcription assay. The plasmid containing the 267-bp HER-2 / neu promoter includes the transcription start site and was used for in vitro transcription. NotI digestion ofthis plasmid yields a 610-bp fragment with 368 bp downstream of the transcription start site and will yield an RNA transcript of approximately this size in run-offtranscription. The template DNA (1 Aig) was incubated with varying concentrations ofthe triplex-forming oligonucleotide or a purine-rich control oligonucleotide in a buffer identical to the one used for gel shift analysis for I h at 370C. As another control, a cytomegalovirus promoter template ( 100 ng) yielding a 363-base transcript (Promega Biotec, Madison, WI) was handled identically to the HER-2/neu template. As discussed in Results below, we found high concentrations of several oligonucleotides to inhibit transcription in this assay system nonspecifically. Therefore, after triplex formation, the template DNA was passed through a spin column with a nominal molecular weight cut offof 100 bp (Chromaspin -100 in DEPC H20; Clontech) as described by the manufacturer. This column allows the template DNA and annealed TFO to pass through into DEPC H20 while retaining -90% of excess oligonucleotide and 99% of the buffer ions. After purifying the template DNA from excess oligonucleotide, transcription reactants were added to achieve a final volume of 75 til with final concentrations 
Results
Triplex formation and its effects on protein binding to the HER-2 / neu promoter were demonstrated by gel mobility shift and DNaseI protection assays. The triplex target site in the HER-2/neu promoter is a purine-rich sequence from -42 to -69 as illustrated in Fig. 1 . The triplex-forming oligonucleotides include the antiparallel and linker substituted antiparallel sequences illustrated in Fig. 2 . The parallel oligonucleotide (Fig. 2 ) was used as a control oligonucleotide that would not form triplex with the target sequence.
Gel mobility shift analysis using oligonucleotides reveals concentration dependent triplex formation by the antiparallel polypurine strand targeted to the HER-2/neu promoter sequence (Fig. 3) . Gel shifts were performed by adding successively greater concentrations of the parallel or antiparallel purine-rich oligonucleotides to the triplex target sequence labeled on the pyrimidine-rich strand under the conditions described. The parallel purine-rich oligonucleotide is identical to the purine-rich strand of the target sequence in both sequence and orientation; the antiparallel oligonucleotide is identical in sequence, but reversed in orientation with respect to the purinerich strand of the target sequence (Fig. 2) . Triplex formation occurs when the triplex-forming oligonucleotide is at 3.3 X l0-7 M concentration ( 100-fold excess with respect to the duplex concentration), and the shift is complete at 3.3 X 10-6 M ( 1,000-fold excess). This is consistent with a dissociation S -*D- Figure 3 . Gel mobility shift analysis showing concentration dependent triplex formation. In all lanes, the 28-base pyrimidine rich strand ofthe target sequence is labeled. The labeled strand was annealed to its purine-rich complement, and the parallel or antiparallel purine rich oligonucleotides were added as described in Methods. Single and double strand controls were included. The concentration of the target sequence was constant at 5 X 10-9 M for the control lane and parallel lanes and at 3.3 x 10-9 M (numbers in figure have been truncated for clarity) in the antiparallel lanes. The oligonucleotide added, its concentration, and its molar ratio to the target DNA are indicated. S, single strand DNA; D, duplex DNA; T, triplex DNA.
constant (Kd) of 4.5 X 10-' M. The antiparallel oligonucleotide was found to be triplex forming, but the parallel oligonucleotide failed to demonstrate triplex formation at concentrations up to 5 X I0-5 M ( 10,000-fold excess).
The sequence specificity of triplex formation was confirmed by DNase I protection footprinting (Fig. 4) . A 267-bp fragment of the HER-2/neu promoter was labeled on either the coding or noncoding strand and incubated with increasing concentrations of the triplex-forming oligonucleotide before limited digestion by DNase I. Protection ofthe target sequence by the triplex-forming oligonucleotide was observed to be concentration dependent in a manner consistent with the gel mobility shift analysis. Protection from digestion is demonstrated at 10-6 M concentration of the antiparallel oligonucleotide, the concentration at which the target duplex was completely shifted to DNA triplex in the gel shift experiments. The parallel polypurine oligonucleotide, however, did not protect the HER-2/neu promoter fragment from DNase I digestion at the same concentration.
The effect of triplex formation on protein binding to the HER-2/neu promoter was evaluated. Gel mobility shift analysis of a 120-bp restriction fragment of the HER-2/neu promoter incubated with a HeLa nuclear extract shows several shifted bands representing different protein-DNA complexes (Fig. 5) . Protein binding was inhibited by preincubation ofthe HER-2/neu promoter fragment with the triplex-forming antiparallel oligonucleotide at a concentration of 5 x 10-6 M ( 1,000-fold excess). Prevention of protein binding was shown to depend on the concentration ofthe triplex-forming oligonucleotide. The concentration of oligonucleotide that prevents protein binding is consistent with the concentration that induced complete triplex formation in the experiments described above. The parallel polypurine oligonucleotide did not prevent protein binding at this concentration.
Protein binding directly to the 28-bp target sequence was demonstrated in gel mobility shift analysis (Fig. 6) . HeLa The effects of triplex formation were examined in an in vitro "run off" transcription assay (Fig. 7) . In this assay, a eukaryotic promoter is incubated with a HeLa nuclear extract in the presence of nucleotide triphosphates; transcripts are labeled by the incorporation of 32P-GTP and correspond in size to the length ofthe template DNA. A NotI digest ofthe plasmid containing the HER-2/neu promoter yields a 6 10-bp fragment with 368 bp downstream of the transcription start site (thus yielding a 368-base transcript). When this promoter fragment was incubated with the triplex forming oligonucleotide, a concentration dependent inhibition of HER-2/neu transcription was observed (Fig. 7 A) . Substantial inhibition oftranscription * w: Figure 4 . DNase I footprints of triplex formation by the antiparallel purine-rich oligonucleotide in the HER-2/neu promoter. 267-bp fragments of HER-2/ neu promoter were labeled and incubated with the oligonucleotides as described. Limited DNAse I digestion was performed, then the DNA was resolved on an 8% polyacrilamide sequencing gel 8 M in urea followed by autoradiography. Maxam-Gilbert sequencing reaction were performed (G and C) and were run simultaneously for orientation; the target sequence is indicated. Concentration and molar ratio of the oligonucleotides with respect to the HER-2/ neu promoter fragment are indicated. The parallel purine-rich oligonucleotide was included as a control.
was seen with oligonucleotide concentrations of 2.5 ,uM and complete inhibition of transcription is seen when the oligonucleotide concentration is 25 ,gM. A purine-rich control (nontriplex-forming) oligonucleotide targetted to an adjacent potential triplex site in the HER-2/neu promoter had no effect on in vitro transcription at 25 IM. It has been shown that DHFR transcription in vitro is enhanced when the template DNA is a digested plasmid containing both the promoter and the plasmid backbone (30) . We observed similar results with HER-2/ neu. Using digested plasmid DNA as the template, high molecular weight bands are observed at -600 and 1,500 bases; presumably these bands represent interaction of the protein extract with the plasmid backbone and similar high molecular weight bands have been observed in DHFR transcription in vitro (30) . In contrast, two lower molecular weight transcripts of -250 and 150 bases represent premature termination of transcription. These lower molecular weight transcripts are also specifically inhibited by the triplex-forming oligonucleo- cleotide is retained in the column (data not shown). Template DNA purified in this way retains full promoter activity in the absence of triplex.
The triplex target sequence in the HER-2/neu promoter contains a single pyrimidine residue at -54 (Fig. 1) . This thymidine residue is unable to Hoogsteen bond with the corresponding thymidine residue of the antiparallel triplex forming oligonucleotide, interrupting the R:R:Y triplex motif at this site. We sought to bridge this pyrimidine interruption with an abasic molecule that preserves internucleotide spacing, and compare the relative triplex forming ability of the substituted oligonucleotide with the unsubstituted oligonucleotide.
Triplex formation by the oligonucleotide with the abasic linker substitution was demonstrated by gel mobility shift analysis (Fig. 8) . Again, a concentration dependent shift to triple helix formation was observed. The linker substituted oligonucleotide induces triplex formation at a concentration of l1-0 M, with a complete shift to triplex at o0-6 M. This is consistent with a Kd of -5 x 10-7 M. Therefore, the binding affinity of the linker substituted oligonucleotide was approximately equivalent to the affinity of the unsubstituted oligonucleotide.
Discussion
We have demonstrated the formation of an interstrand DNA triplex of the R:R:Y type by a polypurine oligonucleotide taroligonucleotide added DNA + II DNA extract alone alone AP P Figure 5 . Gel mobility shift analysis demonstrating protein binding by a nuclear extract to the HER-2 / neu promoter. A 1 9-bp fragment of the HER-2 / neu promoter was labeled and incubated with a HeLa nuclear extract as described. In the "oligonucleotide added" lanes, the DNA was preincubated with the antiparallel or parallel purinerich oligonucleotides at the concentrations indicated. Arrows indicate protein-DNA complexes that are prevented by the triplex formation.
tide in a concentration dependent manner. To further demonstrate the specificity of the oligonucleotide effect on transcription, the CMV promoter was used as a negative control (Fig. 7   B) . A 363-base transcript is synthesized from this CMV template in vitro, and neither the triplex-forming oligonucleotide nor the control oligonucleotide had an effect on CMV transcription in this assay system. It should be mentioned that large excesses of several oligonucleotides (triplex-forming and non-triplex-forming) had a nonspecific inhibitory effect on the in vitro transcription of both the HER-2/neu and CMV genes (data not shown). This nonspecific effect was overcome by purifying the template DNA from excess oligonucleotide by molecular-sieve chromatography. Specifically, the template DNA was incubated with the oligonucleotide and then passed through a spin column with a nominal molecular weight cut off of 100 bp (50 kD). Oligonucleotide bound to the template DNA passed through the column as a stable triplex, while > 90% ofunbound oligonu- The pyrimidine-rich strand of the target sequence was synthesized, ( 14, 22) . Triplex formation in the c-myc promoter of cultured HeLa cells has recently been reported (22) . In this setting, triplex-forming oligonucleotides may have potential application as agents that target a gene in a sequence specific manner and prevent gene expression by inhibiting transcription. Inhibition of in vitro and in vivo transcription of another biologically and clinically important oncogene, c-myc, has already been demonstrated with triplex formation ( 14, 22) . We have shown the specific inhibition ofHER-2/neu transcription in vitro through triplex formation.
The target sequence for triplex formation in the HER-2/ neu oncogene reported here is likely to be important for the regulation and efficient transcription of the HER-2/neu gene. We have shown that this sequence is a binding site for a nuclear protein. The identity of the protein and its significance are not known, but the sequence homology with the TC factor recognition site in the EGF-R promoter ( 13) suggest that it may be of importance in HER-2/neu expression. Inhibition of HER-2/ neu transcription by triplex formation may occur by blocking the binding ofthis protein, which may be a transcription factor necessary for efficient HER-2/neu expression. In addition, the triplex target site is flanked by two important and well-recognized transcription factor recognition sites, the CCAAT sequence (recognition site for the protein CTF) and the TATA box (recognition site for the essential transcription factor TFIID) (Fig. 1) . Triplex formation in the target region may have an effect on the nearby binding of these two factors by changing the local DNA conformation of the flanking sequences, thereby preventing formation ofthe transcription initiation complex whereby RNA polymerase recognizes the transcription start site (+ 1) to begin RNA synthesis (31 ) . Finally, triplex formation may affect the DNA conformation at distal sites (31 ) ; triplex formation at the target site of HER-2/neu may therefore prevent RNA polymerase II itself from binding to the DNA template.
An important limitation to the application oftriplex formation to naturally occurring DNA sequences is the requirement for polypurine:polypyrimidine tracts. Although these sequences occur in nature, naturally occurring polypurine tracts are frequently interrupted by one or several pyrimidines. These pyrimidine residues could disrupt triplex formation in an otherwise favorable triplex target site by loss of triplet hydrogen bonds and unfavorable steric interaction of the pyrimidines (26) . We have examined an abasic linker molecule that could provide a bridge over the pyrimidine interruptions that often are found in naturally occurring purine-rich sequences. Recently, a neutral abasic linker was reported to substitute for a base in a polypyrimidine triplex forming oligonucleotide in a Y:R:Y triplex motif (32 (32) . The Hoogsteen bonding responsible for triplex formation can be expected to confer gene specificity on a triplex-forming oligonucleotide. The conditions of R:R:Y triplex formation suggest that it may be possible to target an oligonucleotide to the promoter of a living cell. Triplex formation may represent an important tool for modulation of gene expression in a gene specific manner. The data presented in this report suggest the potential future application of this tool in the specific modulation of HER-2/neu expression.
